AMEDES acquired by OMERS
Context
A consortium led by Goldman Sachs Asset Management and OMERS Infrastructure acquired amedes from Antin Infrastructure Partners. The transaction valued roughly doubling its value since Antin's entry in 2015. The deal aims to support amedes' continued growth through digitalization and further consolidation of the European lab market.
In the past, Amedes underwent an LBO led by Antin Infrastructure in 2015.
AMEDES, which reported an EBITDA margin of in 2020, is valued in this transaction at an EV/EBITDA multiple of , a level to compare with the average currently observed in the Healthcare & Pharma sector (15.6x).
-> Deep-dive in Healthcare & Pharma market trends
Target
Amedes is one of the leading platforms for medical diagnostics in Germany. It has 35 laboratories and 27 practices across Germany and Belgium.
Ent. Value
Equity Value
Multiples
EV / Revenue
EV / EBITDA
EV / EBIT
Historical Financials (EUR)
Other operations with AMEDES
| Date | Acquirer | Target | Country | Sector |
|---|---|---|---|---|
| 07/2015 | ANTIN INFRASTRUCTURE | AMEDES | GERMANY | Labs (Biology) |
REFERENCES
Valuation range: EV 1b - 4b EUR
Revenue range: 100M - 200M EUR
Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of AMEDES by OMERS are reserved for mynth community members. Register for free to unlock full data.
Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.
Acquirer: omers